IRB White Papers & Case Studies

11. The India Opportunity 9/19/2011
    The total worldwide R&D spending for pharmaceutical and biotech companies (Pharma) in 2007 was $117B, of which 70% represented development costs.
12. White Paper: Foreign Clinical Trial Data 8/5/2011
    Given the high cost of moving a promising drug candidate through years of clinical trials, it’s no wonder that more and more drug manufacturers have begun conducting at least some of their clinical trials in foreign countries. With lower costs and shorter recruiting times, the use of foreign sites is appealing to all drug developers, but especially to those involved in generic and “fast-track” approval programs.